Base de dados : MEDLINE
Pesquisa : D27.505.954.483.620 [Categoria DeCS]
Referências encontradas : 892 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 90 ir para página                         

  1 / 892 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458356
[Au] Autor:Hayashi H; Suzuki A; Ohata K; Ishihara M; Kubota Y; Kobayashi R; Shibata Y; Nakamura H; Nakamura N; Kitagawa J; Tsurumi H; Shimizu M; Itoh Y
[Ad] Endereço:Department of Pharmacy, Gifu University Hospital.
[Ti] Título:Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin's Lymphoma.
[So] Source:Biol Pharm Bull;40(5):698-702, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Management of constipation in patients receiving cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) or CHOP-like chemotherapy regimens is important for prevention of paralytic ileus. We reported earlier that the laxative action of magnesium oxide is reversed by the concomitant use of antacids in cancer patients receiving opioid analgesics. Here, we assessed the prevalence of prophylactic laxative medication for the control of constipation in patients receiving CHOP or CHOP-like regimens for non-Hodgkin's lymphoma. Data obtained from 211 eligible patients were retrospectively analyzed. Almost all patients (99%) received anti-ulcer agents such as proton pump inhibitors and H receptor antagonists for the prophylaxis of gastric disorders associated with prednisolone. Prophylactic laxatives were prescribed in 86 patients (40.8%), in which magnesium oxide was used most predominantly (88.4%). However, magnesium oxide at doses of ≦2000 mg/d was not effective for prevention of constipation, although the compound totally inhibited the incidence of constipation at doses higher than 2000 mg/d. Therefore, it is important to avoid negative drug interaction between magnesium oxide and antacids in patients receiving CHOP chemotherapy.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Constipação Intestinal/induzido quimicamente
Constipação Intestinal/prevenção & controle
Laxantes/uso terapêutico
Linfoma não Hodgkin/complicações
Linfoma não Hodgkin/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antiácidos/uso terapêutico
Constipação Intestinal/epidemiologia
Ciclofosfamida/efeitos adversos
Doxorrubicina/efeitos adversos
Feminino
Seres Humanos
Incidência
Óxido de Magnésio/uso terapêutico
Masculino
Meia-Idade
Prednisona/efeitos adversos
Estudos Retrospectivos
Vincristina/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antacids); 0 (Laxatives); 3A3U0GI71G (Magnesium Oxide); 5J49Q6B70F (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-01001


  2 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28756692
[Au] Autor:Serrano-Falcón B; Rey E
[Ad] Endereço:a Department of Digestive Diseases, Hospital Clinico San Carlos , Complutense University, Instituto de Investigacion Sanitaria San Carlos (IdISSC) , Madrid , Spain.
[Ti] Título:The safety of available treatments for chronic constipation.
[So] Source:Expert Opin Drug Saf;16(11):1243-1253, 2017 Nov.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Chronic constipation is a frequent syndrome which, not only causes an appreciable deterioration in quality of life, but also entails a high economic cost due, among other things, to its treatment. This is because of the widespread use of laxatives, even by subjects who have not sought medical care, as well as little patient satisfaction with the treatment. Although this generally involves the use of drugs regarded as safe, there is no clear evidence about their short- and long-term effects, something that complicates appropriate prescription and follow-up by health professionals and hinders therapeutic compliance. OBJECTIVE: To review the adverse effects which have been associated with laxatives based on scientific evidence, and ascertain the safety profile of the treatments used for constipation. Expert opinion: While all the drugs currently available for treatment of constipation are generally safe when used at established doses under medical supervision, more rigorous data on their long-term safety are nonetheless required, in view of the fact that constipation is a chronic condition. Their long-term use should be monitored by health professionals to optimize treatment on an individualized basis, with the aim of enhancing efficacy and minimizing adverse effects.
[Mh] Termos MeSH primário: Constipação Intestinal/tratamento farmacológico
Laxantes/uso terapêutico
Qualidade de Vida
[Mh] Termos MeSH secundário: Animais
Doença Crônica
Seres Humanos
Laxantes/administração & dosagem
Laxantes/efeitos adversos
Satisfação do Paciente
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Laxatives)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2017.1361402


  3 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28705742
[Au] Autor:Dekkers BGJ; Eck RJ; Ter Maaten JC; Touw DJ
[Ad] Endereço:Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: B.G.J.Dekkers@umcg.nl.
[Ti] Título:An acute oral intoxication with haloperidol decanoate.
[So] Source:Am J Emerg Med;35(9):1387.e1-1387.e2, 2017 Sep.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Haloperidol decanoate is a typical antipsychotic drug used as maintenance therapy for schizophrenia and mood disorders formulated as an ester for intramuscular injection. Cases of oral haloperidol decanoate intoxications have not been described in literature. In this report, we present for the first time a case of an oral ingestion of haloperidol decanoate of a young woman who presented to the emergency department following an intentional oral ingestion of 1 ampoule of haloperidol decanoate 100mg. At presentation, she had a bilateral rest tremor of both hands and mild hypothermia. No other obvious signs of an intoxication were observed. She was treated with a single dose of activated charcoal and laxative and was admitted to the intensive care for rhythm monitoring and observation. During the night the QTc interval increased to 453ms, but stayed within the normal range. Haloperidol plasma levels increased as well, but also stayed within therapeutic ranges. These findings indicate that treatment with oral activated charcoal was sufficient to prevent any serious events.
[Mh] Termos MeSH primário: Antipsicóticos/envenenamento
Carvão Vegetal/uso terapêutico
Haloperidol/análogos & derivados
Laxantes/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Arritmias Cardíacas/induzido quimicamente
Eletrocardiografia
Feminino
Haloperidol/envenenamento
Seres Humanos
Masculino
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Laxatives); 16291-96-6 (Charcoal); AC20PJ4101 (haloperidol decanoate); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE


  4 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Rodrigues, Maria Aparecida Marchesan
Texto completo
[PMID]:28700491
[Au] Autor:Lourenção PLTA; Ortolan EVP; Rosa LLM; Angelini MC; Terra SA; Rodrigues MAM
[Ad] Endereço:aDiscipline of Pediatric Surgery-Department of Surgery and Orthopedics bBotucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil cDepartment of Pathology, Botucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil.
[Ti] Título:Long-term follow-up of patients with intestinal neuronal dysplasia type B: Protocol for an observational, ambispective, and comparative study.
[So] Source:Medicine (Baltimore);96(28):e7485, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intestinal neuronal dysplasia type B (IND-B) is a pathological entity of the group of gastrointestinal neuromuscular diseases characterized by complex alterations in the enteric nervous system. Patients typically present with intestinal constipation, sometimes complicated by episodes of intestinal obstruction. The 2 therapeutic modalities include conservative clinical treatment and surgical treatment. Nevertheless, the results of the different therapeutic modalities are conflicting, and follow-up studies are scarce and include only a limited number of patients.This is a single-center, ambispective, observational, longitudinal, and comparative follow-up study to compare the results of conservative clinical and surgical treatments in patients with IND-B. Sixty-three patients (<15 years) who received this diagnosis will be included. These patients will be divided into 2 groups according to the type of treatment that they previously received: 29 patients in the surgical treatment group and 34 patients in the conservative treatment group. Previous data will be recovered from the medical records of the study patients, including signs and symptoms present at the time of diagnosis, particularly those related to bowel habits, and treatments undergone. Later, these patients will be invited to participate in a semistructured interview during which aspects related to the long-term functional results of the bowel habit and quality of life will be investigated after a minimum interval of 5 years posttreatment.This project aims to assess the long-term clinical evolution of patients diagnosed with IND-B and compare the results obtained following conservative clinical and surgical treatments.This protocol will provide sufficient data to analyze the long-term clinical outcome obtained through the 2 treatment modalities proposed for patients with IND-B.
[Mh] Termos MeSH primário: Enteropatias/terapia
Doenças do Sistema Nervoso/terapia
[Mh] Termos MeSH secundário: Adolescente
Criança
Tratamento Conservador
Seguimentos
Seres Humanos
Entrevistas como Assunto
Enteropatias/cirurgia
Laxantes/uso terapêutico
Estudos Longitudinais
Doenças do Sistema Nervoso/cirurgia
Seleção de Pacientes
Estudos Prospectivos
Qualidade de Vida
Estudos Retrospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Laxatives)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170730
[Lr] Data última revisão:
170730
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007485


  5 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28483009
[Au] Autor:Allen C; Zarowitz BJ; O'Shea T; Datto C; Olufade T
[Ti] Título:Clinical and Functional Characteristics of Nursing Facility Residents with Opioid-Induced Constipation.
[So] Source:Consult Pharm;32(5):285-298, 2017 May 01.
[Is] ISSN:0888-5109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Our goal was to determine the prevalence, clinical characteristics, and treatment differences of opioid-induced constipation (OIC) in older adults with noncancer pain compared with opioid-treated patients without OIC. DESIGN: Retrospective database analysis. SETTING: United States nursing facilities: Patients, Participants, facility residents. INTERVENTIONS: None. MAIN OUTCOME MEASURE(S): Minimum data set and prescription claims, pain, impaired cognition, falls, delirium, and drug treatment. RESULTS: We found an OIC prevalence of 8.9%. Nursing facility residents with OIC are more likely to have severe pain (31.3% vs. 29%; P < 0.001), pain in the last 5 days (71.2% vs. 69.2%; P < 0.001), almost constant pain (18.1% vs.13.3%; P < 0.001), and pain interfering with daily activities (36.1% vs. 30%; P < 0.001). Strong opioids were more likely prescribed and the duration of use was longer than in non-OIC nursing facility residents. Cognitive impairment (56.3% vs. 49.8%; P < 0.001), fall rate (4.8% vs. 2.5%; P = 0.023), delirium indicators (confusion assessment method; P < 0.001), urinary incontinence (59.1% vs. 54.9%; P < 0.001), depression (66.5% vs. 61.6%; P < 0.001), and depression severity score (4.7% vs. 4.3%; P < 0.001) were higher in nursing facility residents with OIC. Nursing facility residents with OIC had a higher percentage of concomitantly prescribed anticholinergic medications (76.7% vs. 70.0%; P < 0.001) and a higher mean anticholinergic burden score (1.4% vs. 1.1%; P < 0.001). Over-the-counter laxatives were used more often than prescription laxatives: polyethylene glycol (43%), docusate (31.1%), and senna/sennosides (23%) vs. lactulose (18.1%) and lubiprostone (2.2%). CONCLUSION: Nursing facility residents with OIC experience suboptimal pain relief, additional anticholinergic adverse drug-related effects, and a decreased quality of life.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Constipação Intestinal/induzido quimicamente
Defecação/efeitos dos fármacos
Instituição de Longa Permanência para Idosos
Pacientes Internados
Casas de Saúde
Dor/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Antagonistas Colinérgicos/efeitos adversos
Comorbidade
Constipação Intestinal/tratamento farmacológico
Constipação Intestinal/epidemiologia
Constipação Intestinal/fisiopatologia
Estudos Transversais
Bases de Dados Factuais
Feminino
Seres Humanos
Laxantes/uso terapêutico
Masculino
Meia-Idade
Dor/diagnóstico
Polimedicação
Prevalência
Qualidade de Vida
Estudos Retrospectivos
Fatores de Risco
Índice de Gravidade de Doença
Resultado do Tratamento
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Cholinergic Antagonists); 0 (Laxatives)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170510
[St] Status:MEDLINE
[do] DOI:10.4140/TCP.n.2017.285


  6 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28432812
[Au] Autor:Feng H; Zhu Y; Fu Z; Li D
[Ad] Endereço:Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
[Ti] Título:Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery.
[So] Source:Chem Biol Drug Des;90(5):867-872, 2017 Nov.
[Is] ISSN:1747-0285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In this study, rhein-SLNs were successfully produced by hot homogenization followed by ultrasonication. Precirol ATO5 in which rhein exhibited higher partition coefficient was selected for preparation of SLNs. In the dynamic light scattering, the rhein-SLNs showed a smaller size with a mean value of 120.8 ± 7.9 nm and with zeta potential of -16.9 ± 2.3 mV. SLNs exhibited a good stability during the period of 2 months. The SLNs indicated faster drug release with a burst release within 2 hr and followed by a sustained release with a biphasic drug-release pattern. Comparing with the same concentration (free drug), the cellular cytotoxicity of rhein-loaded SLNs increased significantly at the same incubation condition. In vivo, the AUC of rhein in the form of SLNs was significantly increased and was 2.06-fold that of suspensions group. The results showed an increased oral absorption and improved the oral bioavailability of rhein by the formulation of SLNs.
[Mh] Termos MeSH primário: Antraquinonas/administração & dosagem
Antineoplásicos/administração & dosagem
Portadores de Fármacos/química
Laxantes/administração & dosagem
Lipídeos/química
Nanopartículas/química
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antraquinonas/química
Antraquinonas/farmacocinética
Antraquinonas/farmacologia
Antineoplásicos/química
Antineoplásicos/farmacocinética
Antineoplásicos/farmacologia
Disponibilidade Biológica
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Laxantes/química
Laxantes/farmacocinética
Laxantes/farmacologia
Masculino
Neoplasias/tratamento farmacológico
Tamanho da Partícula
Coelhos
Solubilidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthraquinones); 0 (Antineoplastic Agents); 0 (Drug Carriers); 0 (Laxatives); 0 (Lipids); YM64C2P6UX (rhein)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE
[do] DOI:10.1111/cbdd.13007


  7 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28414542
[Au] Autor:Emly M; Marriott A
[Ad] Endereço:Chartered Physiotherapist (Recently retired from Leeds and York Partnership Foundation NHS Trust).
[Ti] Título:Revisiting constipation management in the community.
[So] Source:Br J Community Nurs;22(4):168-172, 2017 Apr 02.
[Is] ISSN:1462-4753
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Enfermagem em Saúde Comunitária
Constipação Intestinal/enfermagem
Fibras na Dieta/uso terapêutico
Terapia por Exercício
Hidratação
Laxantes/uso terapêutico
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Seres Humanos
Avaliação em Enfermagem
Qualidade da Assistência à Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Fiber); 0 (Laxatives)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE
[do] DOI:10.12968/bjcn.2017.22.4.168


  8 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28359333
[Au] Autor:Qu C; Yang GH; Zheng RB; Yu XT; Peng SZ; Xie JH; Chen JN; Wang XF; Su ZR; Zhang XJ
[Ad] Endereço:School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China.
[Ti] Título:The immune-regulating effect of Xiao'er Qixingcha in constipated mice induced by high-heat and high-protein diet.
[So] Source:BMC Complement Altern Med;17(1):185, 2017 Mar 31.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Xiao'er Qixingcha (EXQ) has been extensively applied to relieve dyspepsia and constipation in children for hundreds of years in China. However, the therapeutic mechanism underlying its efficacy remained to be defined. The present study aimed to clarify the possible laxative and immune-regulating effects of EXQ on two models of experimental constipation in mice, which mimicked the pediatric constipation caused by high-heat and high-protein diet (HHPD). METHODS: The two models of constipated mice were induced by HHPD or HHPD + atropine respectively. To investigate the laxative and immune-regulating activities of EXQ, animals were treated with three doses of EXQ (0.75, 1.5 and 3 g/kg) for 7 consecutive days. The fecal output parameters (number and weight), weight of intestinal content and, the thymus and spleen indexes were measured. The levels of sIgA, IL-10, TNF-α and LPS in colon and serum were determined by ELISA. Furthermore, the pathological changes of colon tissue were examined after routine H&E staining. RESULTS: Both HHPD and HHPD + atropine treatments obviously inhibited the fecal output and reduced the colonic sIgA, prominently increased the levels of IL-10 and TNF-α in colonic tissue and elevated the contents of LPS in serum and colonic tissues. In contrast, oral administration of EXQ significantly improved the feces characters and dose-dependently decreased the intestinal changes in both models. In HHPD model test, EXQ efficaciously boosted the sIgA level in a dose-dependent manner, significantly elicited decreases in TNF-α and IL-10 levels, and evidently decreased the spleen and thymus indexes. In HHPD + atropine model test, EXQ treatment reversed the pathological changes by not only dramatically decreasing the spleen index and the levels of LPS and IL-10, but also markedly elevating the thymus index. Furthermore, microscopic observation revealed that EXQ treatment maintained the integrity of colonic mucosa, and protected the colonic tissues from inflammation in the both models. CONCLUSIONS: EXQ exhibited prominent laxative activity and effectively protected the colonic mucosal barrier in two models of constipated mice, of which the mechanism might be closely associated with its propulsive and immune-regulating properties. The current results not only validated the rationale for the clinical application of EXQ in pediatric constipation related symptoms, but also threw new light on the immune-inflammatory responses accompanied with chronic constipation pathology.
[Mh] Termos MeSH primário: Constipação Intestinal/tratamento farmacológico
Constipação Intestinal/imunologia
Medicamentos de Ervas Chinesas/administração & dosagem
Fatores Imunológicos/administração & dosagem
Laxantes/administração & dosagem
[Mh] Termos MeSH secundário: Animais
China
Colo/efeitos dos fármacos
Colo/imunologia
Citocinas/imunologia
Dieta
Proteínas na Dieta/efeitos adversos
Proteínas na Dieta/análise
Temperatura Alta
Seres Humanos
Intestinos
Masculino
Camundongos
Baço/efeitos dos fármacos
Baço/imunologia
Timo/efeitos dos fármacos
Timo/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Dietary Proteins); 0 (Drugs, Chinese Herbal); 0 (Immunologic Factors); 0 (Laxatives)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-1700-9


  9 / 892 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346570
[Au] Autor:Chassagne P; Ducrotte P; Garnier P; Mathiex-Fortunet H
[Ad] Endereço:Pr Philippe Chassagne, Department of Geriatrics, Rouen University Hospital, 1 rue de Germont, 76 031 Rouen Cedex, France, Tel.: +33 2 32 88 90 42, E-mail: philippe.chassagne@univ-rouen.fr.
[Ti] Título:Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax®) Compared to Lactulose in Elderly Patients with Chronic Constipation.
[So] Source:J Nutr Health Aging;21(4):429-439, 2017.
[Is] ISSN:1760-4788
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess the tolerance and potential nutritional consequences of long-term repeated doses of PEG 4000 (10 to 30 g/day) in elderly patients with chronic constipation as compared to lactulose (10-30 g/day). DESIGN: Single blind, randomised, multicentre, parallel group comparative study. SETTING: Community-dwelling patients and nursing homes residents aged 70 years and older with a history of chronic constipation. Treatment intervention: PEG 4000 (10-30 g/day) or lactulose (10-30 g/day) for six months. ASSESSMENTS: Clinical nutritional status (Mini Nutritional Assessment), blood and stool samples were taken at baseline and after three and six months for assay of nutritional and absorption parameters. A patient diary documented digestive symptoms and adverse events were recorded. Information on efficacy (stool frequency and consistency) was collected as a secondary outcome measure. RESULTS: Of the 316 patients screened, 245 eligible patients constituted the ITT population (PEG 4000: N = 118; lactulose group: N = 127). The proportion of patients receiving PEG 4000 with abnormal levels of electrolytes, nutritional markers or vitamins did not significantly change in the six months after initiating laxative treatment and do not differ between the two groups. After a D-xylose challenge test, the proportion of patients with abnormally low xylosaemia (suggesting malabsorption) varied from 24.6% at baseline to 35.8% after six months in the PEG 4000 group and from 29.1% to 42.4% in the lactulose group, with no significant between-group or within-group differences. The proportion of patients with poor nutritional status (MNA score <17) varied from 8.5% at baseline to 9.8% after 6 months in the PEG 4000 group and from 3.9% to 5.0% in the lactulose group. No changes in stool fat or total or soluble stool nitrogen were observed in the minority of patients for whom stool analysis was performed. A significantly higher stool frequency (p <0.05) and improved stool consistency (p <0.05) was observed in the PEG 4000 group compared to the lactulose group at each monthly evaluation period. CONCLUSIONS: After six months of treatment with PEG 4000, no clinically relevant changes in biochemical and nutritional parameters and no unanticipated treatment-related adverse events were detected, demonstrating the good clinical tolerance of PEG 4000 in this population of elderly constipated patients. This tolerance was associated with a better clinical efficacy of PEG 4000 compared to lactulose.
[Mh] Termos MeSH primário: Constipação Intestinal/tratamento farmacológico
Lactulose/uso terapêutico
Laxantes/uso terapêutico
Polietilenoglicóis/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Eletrólitos/análise
Fezes/química
Feminino
França
Seres Humanos
Lactulose/efeitos adversos
Laxantes/efeitos adversos
Masculino
Casas de Saúde
Estado Nutricional/fisiologia
Polietilenoglicóis/efeitos adversos
Método Simples-Cego
Resultado do Tratamento
Xilose/sangue
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Electrolytes); 0 (Laxatives); 30IQX730WE (Polyethylene Glycols); 4618-18-2 (Lactulose); 4R4HFI6D95 (polyethylene glycol 4000); A1TA934AKO (Xylose)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1007/s12603-016-0762-6


  10 / 892 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28345979
[Au] Autor:Bardsley A
[Ad] Endereço:Senior Lecturer, Course Director Non-Medical Prescribing, Coventry University.
[Ti] Título:Assessment and treatment options for patients with constipation.
[So] Source:Br J Nurs;26(6):312-318, 2017 03 23.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Constipation is a common complaint for people of all ages, with prevalence increasing with age and during pregnancy. Women are more likely to be affected than men. Severity of constipation varies from person to person; most people experience short periods of constipation during their lives, including possibly after surgery, while others have constipation as a chronic long-term condition that can significantly affect their quality of life. There are a number of factors that can contribute to developing constipation including diets low in fibre, changes in lifestyle, side effects of certain medications and low fluid intake. People can successfully treat constipation by making changes to their diet and lifestyle. However, medication may be required to manage constipation for some.
[Mh] Termos MeSH primário: Constipação Intestinal/enfermagem
Dietoterapia
Laxantes/uso terapêutico
Avaliação em Enfermagem
[Mh] Termos MeSH secundário: Catárticos/uso terapêutico
Constipação Intestinal/diagnóstico
Constipação Intestinal/terapia
Gerenciamento Clínico
Seres Humanos
Lactulose/uso terapêutico
Metilcelulose/uso terapêutico
Peptídeos/uso terapêutico
Polietilenoglicóis/uso terapêutico
Qualidade de Vida
Extrato de Sena/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cathartics); 0 (Laxatives); 0 (Peptides); 30IQX730WE (Polyethylene Glycols); 4618-18-2 (Lactulose); 8013-11-4 (Senna Extract); 9004-67-5 (Methylcellulose); N0TXR0XR5X (linaclotide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.6.312



página 1 de 90 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde